343 research outputs found
A linear Kalman filtering scheme for estimation of secondary vertical suspension of railway vehicles
Model based filtering is fast becoming a key instrument for maintenance and condition monitoring of railway vehicles. This study presents the use of linear Kalman filtering scheme to identify vertical secondary suspension of a railway vehicle by using the vertical vibrations of a vehicle due to vertical track irregularities. As well as the use of linear Kalman filtering scheme, a weighted least squares estimation is used to identify vertical secondary spring coefficient as a parameter by using residuals of the filter. In this investigation, a 7 degree of freedom dynamic model of ERRI B176 benchmark vehicle is considered. Unlike previous studies, to the authors’ knowledge, this research provides the simplest estimation scheme for identification of secondary vertical spring parameter and can be used to achieve a cost-effective condition based maintenance for railway vehicles
Depressive Symptoms in a General Population: Associations with Obesity, Inflammation, and Blood Pressure
To determine whether obesity, inflammation, or conventional risk factors are related to depressive symptoms (DeprSy) in the general population. Responses to 3 questions served to assess sense of depression. Body mass index (BMI), C-reactive protein (CRP), and other epidemiologic data of participants were available. In 1940, individuals who consulted a psychiatrist in the preceding year, or felt depressed (together DeprSy), 248 were female. Logistic regressions for adjusted associations of BMI with DeprSy were not significant as was serum CRP level. Diabetes and, in men, fasting glucose concentrations were associated with DeprSy. Systolic blood pressure (SBP) was robustly inversely associated with DeprSy in diverse models at ORs of 0.74 (95%CI 0.63; 0.89) independent of confounders, including antihypertensive and lipid-lowering medication. The use of antidepressants could not explain the reduced BP. Women are predisposed to depression with which, not BMI and CRP, but SBP is inversely associated. Anti-inflammatory substances produced in depressed persons might explain the slightly lower BP
Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: Relation to sex hormone-binding globulin
It is unclear whether serum adiponectin concentrations diminish linearly with increasing
adiposity and, if not, which factors codetermine this association. These issues were
investigated cross-sectionally in 1188 men and women, representative of middle-aged and elderly
Turkish adults. Serum total adiponectin was assayed by ELISA. Serum adiponectin values in men,
though declining significantly in transition from the bottom to the mid tertile of body mass
index (BMI) and waist circumference (WC), were similar in the two respective upper tertiles. In
women, serum adiponectin concentrations were not significantly different in any tertile of
these indices, were significantly correlated with BMI or WC within the low tertiles and not
within the two higher tertiles. In a linear regression analysis for WC (or BMI) in a subset of
the sample in which serum sex hormone-binding globulin (SHBG) was available and which
additionally comprised adiponectin, fasting insulin and other confounders, only insulin and, in
women SHBG, were significantly associated, but not adiponectin. In linear regression analyses
for covariates of adiponectin in two models comprising 12 variables, insulin and SHBG
concentrations were significantly associated in both genders though not BMI. Whereas in men
HDL-cholesterol and CRP were covariates of adiponectin (both p<0.01), SHBG and
apolipoprotein B positively associated in women (p<0.001), independent of BMI and
fasting insulin levels
Adeziv güçlendiricinin kompozitin daimi dişe mikrogerilim bağlanma dayanımına etkisi
Amaç: Bu çalışmanın amacı adeziv güçlendiricinin daimi diş
dentinine bağlanma performansını değerlendirmektir.
Gereç ve Yöntemler: Bu çalışmada on adet çürüksüz
mandibular molar diş kullanıldı. Dişlerin okluzal yüzeyleri
tüm mineyi ortadan kalkacak şekilde su soğutması altında
elmas separe ile uzaklaştırılarak dentin yüzeyleri açığa
çıkarıldı. Dentin yüzeyleri 600-800-1000-1200 grit
zımparalarla su altında zımparalandı ve dişler rastgele iki
gruba ayrıldı; Grup 1: Total etch (Adper Scotchbond Multi
Purpose Plus, 3M ESPE, UK), Grup 2: Total etch + adezyon
güçlendirici (Enhance, Reliance, USA). Kompozit rezin
restorasyonlar 4-5 mm yükseklikte olacak şekilde
yerleştirildi. Su içerisinde (37oC) 24 saat bekletilen dişler
1mm2'lik örnekler elde edilecek şekilde kesitler alındı ve 62
örnek elde edildi. Tüm örneklere mikrogerilim bağlanma
testi 1mm/dak hız ile kırılma meydana meydana gelene
kadar uygulandı. Kırılma yüzeyleri stereomikroskop altında
incelendi. İstatistiksel analiz bağımsız t testi ile
değerlendirildi.
Bulgular: Grup 1 ve Grup 2’den elde edilen mikrogerilme
bağlanma dayanımı değerleri sırasıyla 27,47 MPa ve 27,66
MPa olarak kaydedildi. Gruplar arasında istatistiksel olarak
anlamlı farklılık bulunmadı (p > 0,05).
Sonuç: Elde edilen sonuçlara göre Enhance adezyon
güçlendirici kompozit rezinin daimi dişe bağlanma
dayanımını geliştirmemiştir
Farklı yüzey hazırlama yöntemlerinin fissür örtücülerin bağlanma dayanımı üzerine olan etkisi
Amaç: Bu çalışmada amacı kurutma ajanı/ kurutma
ajanı olmaksızın mine yüzeyinin hazırlanmasında
asitle pürüzlendirme ve Er:YAG lazerin (QSP ve
MSP mod) fissür örtücünün bağlanma dayanımı
üzerine etkisini değerlendirmek amaçlandı.
Gereç ve Yöntemler: Bu çalışmada 30 adet
çürüksüz daimi diş kullanıldı. Dişler mine-sement
sınırının 2 mm üstünden kesildi ve kökler
uzaklaştırıldı. Dişler meziodistal olarak ikiye ayrıldı.
Elde edilen 60 yarım diş akrilik reçine içine
gömüldü. Mine yüzeyinde fissure örtücüler için 2
mm çapında alan oluşturuldu. Bütün gruplara
Ultraseal XT plus (Fissür örtücü:FÖ) uygulandı.
Örnekler randomize olarak 6 gruba ayrıldı (n:10);
G1:% 37 fosforik asit + Prima Dry + FÖ, G2:% 37
fosforik asit + FÖ, G3: Er: YAG (MSP modu) +
Prima Dry + FÖ; G4: Er: YAG (MSP modu) + FÖ;
G5: Er: YAG (QSP modu) + Prima Dry + FÖ; G6:
Er: YAG (QSP modu) + FÖ. Örnekler 24 saat distile
su içinde bekletildikten sonra bağlanma kuvvetleri,
üniversal test makinesi ile test edildi. Verileri
karşılaştırmak için Kruskal-Wallis ve Mann-Whitney
U-testi kullanıldı.
Bulgular: Gruplara ait bağlanma dayanımları
şöyledir (MPa) G1: 11.33, G2: 9.76, G3: 8.65, G4:
7.72, G5: 4.49, G6: 2.73. Gruplar arasında
istatistiksel fark olduğu gözlendi (p < 0.05).
Sonuç: Mine yüzeyine asit uygulaması, Er:YAG
lazer QSP ve MSP moda göre daha iyi sonuçlar
verdiği görülmüştür. Fissür örtücü uygulanmadan
önce kurutma ajanı uygulanabilir
Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis
The added value of incorporating information from repeated blood pressure and cholesterol measurements to predict cardiovascular disease (CVD) risk has not been rigorously assessed. We used data on 191,445 adults from the Emerging Risk Factors Collaboration (38 cohorts from 17 countries with data encompassing 1962-2014) with more than 1 million measurements of systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Over a median 12 years of follow-up, 21,170 CVD events occurred. Risk prediction models using cumulative mean values of repeated measurements and summary measures from longitudinal modeling of the repeated measurements were compared with models using measurements from a single time point. Risk discrimination (Cindex) and net reclassification were calculated, and changes in C-indices were meta-analyzed across studies. Compared with the single-time-point model, the cumulative means and longitudinal models increased the C-index by 0.0040 (95% confidence interval (CI): 0.0023, 0.0057) and 0.0023 (95% CI: 0.0005, 0.0042), respectively. Reclassification was also improved in both models; compared with the single-time-point model, overall net reclassification improvements were 0.0369 (95% CI: 0.0303, 0.0436) for the cumulative-means model and 0.0177 (95% CI: 0.0110, 0.0243) for the longitudinal model. In conclusion, incorporating repeated measurements of blood pressure and cholesterol into CVD risk prediction models slightly improves risk prediction
Association of Cardiometabolic Multimorbidity With Mortality.
IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity
Association of Cardiometabolic Multimorbidity With Mortality.
IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity
- …